Literature DB >> 12112778

Cytokine secretion in children with acute Mycoplasma pneumoniae infection and wheeze.

Susanna Esposito1, Roberta Droghetti, Samantha Bosis, Laura Claut, Paola Marchisio, Nicola Principi.   

Abstract

The aim of this study was to evaluate cytokine secretion in children with acute Mycoplasma pneumoniae infection and wheeze. We studied 25 patients aged 2-14 years with an acute episode of wheezing (15 with acute M. pneumoniae infection) and 16 healthy controls of similar gender and age (8 with laboratory evidence of asymptomatic acute M. pneumoniae infection). Serum interleukin (IL)-2, interferon (IFN)-gamma, IL-4, and IL-5 concentrations were measured in samples obtained at enrollment, using enzyme-linked immunosorbent assay kits. In the presence of wheezing, IL-5 concentrations were significantly higher in subjects with acute M. pneumoniae infection (33.415 +/- 22.138 pg/mL) than in those without such infection (2.320 +/- 1.846 pg/mL, P < 0.0001). The children with acute M. pneumoniae infection and wheeze had higher IL-5 concentrations (33.415+/-22.138 pg/mL) than those with asymptomatic acute infection and without wheeze (1.740 +/- 2.299 pg/mL, P < 0.0001). No significant between-group differences were observed in terms of IL-2, IFN-gamma, or IL-4 levels, or the prevalence of atopy. Our results show that children with wheezing and acute M. pneumoniae infection have a specific cytokine profile characterized by a significant increase in serum levels of IL-5. This immune response may be important for understanding the pathophysiological mechanisms by which this pathogen contributes to the development of wheeze-related symptoms, and for identifying new treatment strategies. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12112778     DOI: 10.1002/ppul.10139

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  21 in total

1.  Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains.

Authors:  Chonnamet Techasaensiri; Claudia Tagliabue; Marianna Cagle; Pooya Iranpour; Kathy Katz; Thirumalai R Kannan; Jacqueline J Coalson; Joel B Baseman; R Doug Hardy
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

2.  The Immunopathologic Effects of Mycoplasma pneumoniae and Community-acquired Respiratory Distress Syndrome Toxin. A Primate Model.

Authors:  Diego J Maselli; Jorge L Medina; Edward G Brooks; Jacqueline J Coalson; Thirumalai R Kannan; Vicki T Winter; Molly Principe; Marianna P Cagle; Joel B Baseman; Peter H Dube; Jay I Peters
Journal:  Am J Respir Cell Mol Biol       Date:  2018-02       Impact factor: 6.914

3.  Chlamydophila pneumoniae and Mycoplasma pneumoniae in respiratory specimens of children with chronic lung diseases.

Authors:  N Teig; A Anders; C Schmidt; C Rieger; S Gatermann
Journal:  Thorax       Date:  2005-09-02       Impact factor: 9.139

4.  Changes in the Levels of Interleukin-17 Between Atopic and Non-atopic Children with Mycoplasma pneumoniae Pneumonia.

Authors:  Zhi-Hua Wang; Xin-Min Li; Yu-Shui Wang; Ze-Yang Guo
Journal:  Inflammation       Date:  2016-12       Impact factor: 4.092

Review 5.  Mycoplasma pneumoniae and its role in asthma.

Authors:  Nazima Nisar; Randeep Guleria; Sanjay Kumar; Tirlok Chand Chawla; Nihar Ranjan Biswas
Journal:  Postgrad Med J       Date:  2007-02       Impact factor: 2.401

Review 6.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Atypical bacteria and macrolides in asthma.

Authors:  Paraskevi Xepapadaki; Ioanna Koutsoumpari; Vasiliki Papaevagelou; Christina Karagianni; Nikolaos G Papadopoulos
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

8.  Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.

Authors:  Ana María Ríos; Asunción Mejías; Susana Chávez-Bueno; Mónica Fonseca-Aten; Kathy Katz; Jeanine Hatfield; Ana María Gómez; Hasan S Jafri; George H McCracken; Octavio Ramilo; Robert Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Identification of an N-terminal 27 kDa fragment of Mycoplasma pneumoniae P116 protein as specific immunogen in M. pneumoniae infections.

Authors:  Irum Tabassum; Rama Chaudhry; Bishwanath Kumar Chourasia; Pawan Malhotra
Journal:  BMC Infect Dis       Date:  2010-12-13       Impact factor: 3.090

10.  Airway epithelial NF-κB activation promotes Mycoplasma pneumoniae clearance in mice.

Authors:  Di Jiang; Mark L Nelson; Fabienne Gally; Sean Smith; Qun Wu; Maisha Minor; Stephanie Case; Jyoti Thaikoottathil; Hong Wei Chu
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.